GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Entera Bio Ltd (NAS:ENTX) » Definitions » Cash Ratio

ENTX (Entera Bio) Cash Ratio : 6.22 (As of Sep. 2024)


View and export this data going back to 2018. Start your Free Trial

What is Entera Bio Cash Ratio?

The Cash Ratio measures a company’s ability to meet its short-term obligations with cash and near-cash resources. It is calculated as a company's Cash, Cash Equivalents, Marketable Securities divides by its Total Current Liabilities. Entera Bio's Cash Ratio for the quarter that ended in Sep. 2024 was 6.22.

Entera Bio has a Cash Ratio of 6.22. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.

The historical rank and industry rank for Entera Bio's Cash Ratio or its related term are showing as below:

ENTX' s Cash Ratio Range Over the Past 10 Years
Min: 0.2   Med: 4.67   Max: 12.01
Current: 6.22

During the past 9 years, Entera Bio's highest Cash Ratio was 12.01. The lowest was 0.20. And the median was 4.67.

ENTX's Cash Ratio is ranked better than
71.51% of 1474 companies
in the Biotechnology industry
Industry Median: 2.665 vs ENTX: 6.22

Entera Bio Cash Ratio Historical Data

The historical data trend for Entera Bio's Cash Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Entera Bio Cash Ratio Chart

Entera Bio Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cash Ratio
Get a 7-Day Free Trial Premium Member Only 3.31 4.67 7.87 9.18 10.10

Entera Bio Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24
Cash Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.74 10.10 8.20 7.00 6.22

Competitive Comparison of Entera Bio's Cash Ratio

For the Biotechnology subindustry, Entera Bio's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Entera Bio's Cash Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Entera Bio's Cash Ratio distribution charts can be found below:

* The bar in red indicates where Entera Bio's Cash Ratio falls into.



Entera Bio Cash Ratio Calculation

The Cash Ratio measures a company's ability to meet its short-term obligations with its cash and near-cash resources.

Entera Bio's Cash Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash Ratio (A: Dec. 2023 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=11.019/1.091
=10.10

Entera Bio's Cash Ratio for the quarter that ended in Sep. 2024 is calculated as:

Cash Ratio (Q: Sep. 2024 )=Cash, Cash Equivalents, Marketable Securities/Total Current Liabilities
=6.915/1.111
=6.22

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Entera Bio  (NAS:ENTX) Cash Ratio Explanation

The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.

The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.

In general, the higher the cash ratio, the better the company's liquidity position.


Entera Bio Cash Ratio Related Terms

Thank you for viewing the detailed overview of Entera Bio's Cash Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Entera Bio Business Description

Traded in Other Exchanges
Address
Minrav Building - Fifth Floor, Kiryat Hadassah, Jerusalem, ISR, 9112002
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
Executives
Haya Taitel director KIRYAT HADASSAH, MINRAV BUILDING, 5TH FLOOR, JERUSALEM L3 9112002
Miranda Jayne Toledano director C/O COMPASS THERAPEUTICS, INC., 80 GUEST STREET, SUITE 601, BOSTON MA 02135
Gerald M Lieberman director C/O ALLIANCE CAPITAL, 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105
Sean Ellis director KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Dana Yaacov-garbeli officer: Israel CFO KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Phillip Schwartz director, officer: President of R&D C/O ENTERA BIO LTD., KIRYAT HADASSAH, MINRAV BUILDING, 5TH FL, JERUSALEM L3 9112002
Ramesh Ratan officer: U.S.based CFO KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Ron Mayron director 22A ORANIM ST, HOD HASHARON L3 4526333
Spiros Jamas director, officer: Chief Executive Officer
Gerald M Ostrov director 41 WATERVIEW, LONG BRANCH NJ 07740
Yonatan Malca director KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Roger Garceau director 550 HILLS DRIVE, BEDMINSTER NJ 07921
Hillel Galitzer officer: Chief Operating Officer KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002
Santora Arthur C Ii officer: Chief Medical Officer KIRYAT HADASSAH, MINRAV BUILDING, FIFTH FLOOR, JERUSALEM L3 9112002